HealthLinx Says Sigma-Aldrich Patent Challenge Is Rejected

The European patent covers IgY immunodepletion technology. Sigma-Aldrich has a final opportunity to argue its position in September.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.